Browse the evidence

Higher doses of tirzepatide (10-15 mg), younger age, and female sex are associated with a longer time to reach a weight plateau compared to lower doses (5 mg), older age, and male sex.

If you are on tirzepatide and your weight loss slows down significantly (plateau), do not panic or assume the drug has stopped working. This is a normal physiological adaptation. The study shows that people on higher doses, younger people, and women tend to reach this plateau later because they lose more total weight. Focus on maintaining the negative energy balance rather than chasing rapid scale changes. If you are on a lower dose (5mg), you may plateau sooner than those on 10-15mg, but this does not mean the treatment is ineffective.

The efficacy of GLP-1RA combined with lifestyle modification is influenced by treatment duration, drug type (semaglutide/tirzepatide), dosing frequency (weekly), and geographic region (North America).

For the best weight loss results with GLP-1RAs, choose a weekly formulation (like semaglutide or tirzepatide) if possible, maintain the treatment for at least a year, and ensure your lifestyle intervention is consistent. Regional factors may also play a role in outcomes.

Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) associated with tirzepatide contribute minimally (up to 3.1%) to total weight reduction, with weight loss occurring similarly in patients with and without these symptoms.

Do not expect nausea or vomiting to drive your weight loss. Clinical data shows that patients who experience no gastrointestinal side effects lose just as much weight as those who do. Focus on the hormonal mechanism of the drug rather than tolerating discomfort as a sign of efficacy.

Discontinuation of GLP-1 receptor agonists leads to significant weight regain (approx. two-thirds of lost weight) and loss of cardiometabolic benefits, driven partly by a surge in ghrelin.

If you stop taking GLP-1 medications, you will likely regain most of the weight you lost. This is a physiological response (ghrelin surge), not a failure of willpower. To maintain weight loss, you must either stay on the medication indefinitely or switch to a more durable intervention like surgery.

Semaglutide 2.4 mg weekly reduces all-cause mortality and major adverse cardiovascular events in overweight/obese patients with preexisting cardiovascular disease but no diabetes, yet remains cost-ineffective at current pricing relative to standard care.

For a patient with heart disease and obesity but no diabetes: Semaglutide 2.4mg weekly significantly lowers your risk of heart attack, stroke, and death compared to standard care. However, because the drug is expensive, public health systems may not cover it unless the price drops. You should discuss the clinical benefits with your doctor, but be aware that insurance coverage might be denied or require prior authorization due to cost-effectiveness thresholds.

GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss, leading to improved physical functioning, daily living capacity, and mental well-being, despite common gastrointestinal side effects.

GLP-1RAs are effective for weight loss and improving daily functioning. Expect gastrointestinal side effects like nausea, which often subside after a few weeks. The benefits of weight loss and improved mobility often motivate patients to persist despite these side effects.

Female patients report greater benefits from GLP-1RA treatment compared to male patients, particularly in mental well-being and physical functioning.

Be aware that female patients may report greater improvements in quality of life and mental well-being from GLP-1RAs than male patients. This is a documented trend in patient experiences.

GLP-1RAs improve the management of sweet cravings and reduce emotional eating.

GLP-1RAs can help reduce sweet cravings and emotional eating, making it easier to maintain weight loss. This is a reported benefit by patients.

In healthy young humans, changes in skeletal muscle mass in response to resistance exercise, disuse, and aging are primarily driven by alterations in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged or plays a negligible role.

To maintain or build muscle, prioritize resistance exercise and protein intake to stimulate muscle protein synthesis. You do not need to worry about 'blocking' muscle breakdown as a primary strategy, as your body naturally regulates this, and forcing suppression may be counterproductive. Consistent loading is the key lever.

In aging skeletal muscle, the progressive loss of mass (sarcopenia) is largely driven by anabolic resistance—a desensitized muscle protein synthesis response to stimuli like loading and protein ingestion—rather than increased protein breakdown.

Older adults should prioritize resistance training and adequate protein intake to overcome anabolic resistance. While muscle loss is slower with age, maintaining activity levels can prevent many age-related muscle deficits.

Patients with specific comorbidities, specifically dyslipidaemia and obstructive sleep apnoea (OSA), have significantly higher odds of receiving both anti-obesity medication (AOM) prescriptions and metabolic and bariatric surgery (MBS).

Having comorbidities like high cholesterol or sleep apnea can increase your chances of being prescribed obesity treatments. If you don't have these, you may face more hurdles. Discuss your overall metabolic health with your provider, as obesity itself is a valid reason for treatment.

GLP-1 receptor agonists significantly reduce binge eating behaviors and alcohol consumption, offering therapeutic potential for substance use disorders and eating disorders independent of weight loss.

If you struggle with binge eating or alcohol use, GLP-1 medications might help reduce these cravings directly, not just by making you lose weight. Clinical trials show significant improvements in binge eating scores and reduced alcohol intake. This suggests the drug affects the brain's reward system, offering a new tool for managing these specific behaviors.

Tirzepatide treatment (5-15 mg weekly for 72 weeks) significantly improves both insulin sensitivity and beta-cell function in adults with obesity or overweight (BMI ≥27 kg/m2) with prediabetes or normoglycemia, independent of type 2 diabetes.

If you have obesity or are overweight and have prediabetes or normal blood sugar, tirzepatide (a once-weekly injection) can significantly improve how your body handles insulin and how well your pancreas functions. This happens partly because you lose weight, but also directly from the medication itself, potentially lowering your risk of developing type 2 diabetes.

GIP secretion is robustly stimulated by dietary lipids (fats) via GPR40, GPR120, and GPR119 receptors, with fat inducing a threefold higher GIP response compared to an oral glucose tolerance test.

Fats are the most potent natural trigger for GIP secretion, causing levels to rise three times higher than glucose. This secretion depends on specific receptors (GPR40/120/119) and bile acids.

Time-restricted eating (TRE) improves glucose homeostasis, lipid metabolism, and blood pressure in individuals with metabolic conditions, independent of weight loss.

If you have metabolic risks like prediabetes or high blood pressure, try limiting your daily eating window to 8-10 hours, preferably starting earlier in the day (e.g., 8am-4pm). This timing aligns with your body's natural rhythms and can improve insulin sensitivity and blood pressure, even if your weight doesn't change. Ensure you are eating enough protein within that window to protect muscle mass, especially if you are older.

GLP-1 receptor agonists suppress appetite through a non-aversive neural pathway (NTS GLP1R neurons projecting to PVH) that is distinct from the nausea-inducing pathway (Area Postrema GLP1R neurons projecting to PBN/CeA), allowing for weight loss without nausea.

GLP-1 medications like semaglutide work through two separate brain pathways: one that makes you feel full without feeling sick, and another that causes nausea. You can achieve significant weight loss through the 'fullness' pathway even if you experience some nausea, but the nausea itself isn't required for the fat loss. If nausea is severe, it may indicate you are activating the nausea pathway more than the satiety pathway, and dose adjustments might help optimize the benefit-to-side-effect ratio.

Real-world use of tirzepatide for obesity management without type 2 diabetes involves significantly slower dose escalation and lower adherence compared to clinical trial protocols, with most patients remaining on doses ≤10 mg and roughly half discontinuing treatment within six months.

In real-world practice, tirzepatide is often used at lower doses (≤10 mg) than in clinical trials, and about half of patients stop treatment within six months. If you are using it, expect that dose escalation may be slower than recommended, and persistence is a challenge. If you discontinue, switching to another GLP-1 agonist like semaglutide is a common next step.

In patients with type 2 diabetes, initiating GLP-1 receptor agonists (GLP-1RA) is associated with a significantly higher risk of gastroparesis compared to initiating SGLT2 inhibitors or insulin glargine, while insulin glargine is associated with a higher risk of all-cause mortality compared to GLP-1RA.

If you have type 2 diabetes and are considering a GLP-1RA (like semaglutide or dulaglutide), be aware that these drugs can slow down your stomach emptying, increasing the risk of gastroparesis. This risk is higher with GLP-1RA than with SGLT2 inhibitors (like empagliflozin) or insulin glargine. However, GLP-1RA is associated with a lower risk of death compared to insulin. If you are already at risk for gastroparesis, talk to your doctor about SGLT2 inhibitors as a first-line alternative to GLP-1RA.

Emerging pharmacotherapies, specifically GLP-1 receptor agonists and multi-agonists, induce 15-25% weight loss, challenging the necessity of bariatric surgery for patients with BMI 30-40 kg/m2.

If you have obesity (BMI 30-40) and are considering surgery, discuss GLP-1 based medications (like semaglutide or tirzepatide) with your doctor. These drugs can produce 15-25% weight loss, which is comparable to surgery, offering a non-surgical option with significant metabolic benefits.

Current bariatric surgery guidelines (BMI >= 35, or 30-34.9 with comorbidities) may need re-evaluation due to the efficacy of pharmacotherapy.

If your BMI is between 30 and 40, you may not need surgery. Ask your doctor about GLP-1 medications, which are now effective enough to potentially replace surgery for many patients.

Women experience a significantly lower efficacy-to-tolerability ratio than men when treated with GLP-1 receptor agonists, characterized by disproportionately higher rates of persistent nausea and vomiting relative to weight loss.

If you are a woman taking a GLP-1 medication like semaglutide or tirzepatide, you are statistically more likely to experience nausea and vomiting than a man taking the same drug, even if you lose more weight. This is not a failure of willpower but a biological difference in how your body processes the drug, likely driven by estrogen levels. Discussing this with your provider may lead to strategies like slower dose escalation or phase-specific dosing to manage side effects.

Tirzepatide treatment significantly reduces food cravings and preferences for energy-dense foods (high fat, high sugar, fast food fats) in people with obesity, independent of caloric restriction.

If you struggle with intense cravings for high-fat or high-sugar foods, tirzepatide can help reduce these urges. This isn't just about willpower; the medication physiologically lowers the 'pull' of these foods, making it easier to stick to a healthy diet.

Tirzepatide specifically reduces cravings for fast-food fats (e.g., pizza, hamburgers) more than other high-fat foods (e.g., sausage, fried fish).

Tirzepatide may be particularly effective at reducing cravings for specific fast-food items like pizza and burgers compared to other high-fat foods.

GLP-1 receptor agonist (GLP-1RA) treatment in obese individuals causes a modest absolute decrease in skeletal muscle mass, but preserves or improves relative muscle mass and strength, resulting in maintained or enhanced physical performance.

If you are taking GLP-1 medications for weight loss, expect a small, normal amount of muscle loss alongside your fat loss. This is not pathological wasting; your muscles are actually working better relative to your new body weight. Focus on maintaining strength through activity, as your mobility and endurance may actually improve.